Patents by Inventor Yoshiko Kagoshima
Yoshiko Kagoshima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230074669Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.Type: ApplicationFiled: November 24, 2021Publication date: March 9, 2023Applicant: Daiichi Sankyo Company, LimitedInventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
-
Publication number: 20230030720Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.Type: ApplicationFiled: December 5, 2019Publication date: February 2, 2023Applicant: Daiichi Sankyo Company, LimitedInventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
-
Patent number: 11274100Abstract: The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.Type: GrantFiled: June 21, 2018Date of Patent: March 15, 2022Assignee: Daiichi Sankyo Company, LimitedInventors: Hiroyuki Naito, Yoshiko Kagoshima, Hideaki Funami, Akifumi Nakamura, Masayoshi Asano, Makoto Haruta, Takashi Suzuki, Jun Watanabe, Ryutaro Kanada, Saito Higuchi, Kentaro Ito, Akiko Egami, Katsuhiro Kobayashi
-
Patent number: 11236106Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.Type: GrantFiled: April 28, 2021Date of Patent: February 1, 2022Assignee: Daiichi Sankyo Company, LimitedInventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
-
Publication number: 20210269454Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.Type: ApplicationFiled: April 28, 2021Publication date: September 2, 2021Applicant: Daiichi Sankyo Company, LimitedInventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
-
Publication number: 20210171520Abstract: The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.Type: ApplicationFiled: June 21, 2018Publication date: June 10, 2021Applicant: Daiichi Sankyo Company, LimitedInventors: Hiroyuki Naito, Yoshiko Kagoshima, Hideaki Funami, Akifumi Nakamura, Masayoshi Asano, Makoto Haruta, Takashi Suzuki, Jun Watanabe, Ryutaro Kanada, Saito Higuchi, Kentaro Ito, Akiko Egami, Katsuhiro Kobayashi
-
Patent number: 10399968Abstract: Problem to be Solved There is a need for a new antibiotic having a novel mechanism of action which exhibit strong antibacterial activity not only against sensitive bacteria but also against resistant bacteria thereof, and at the same time possesses excellent solubility an a safety profile amenable to human use. Solution to the Problem As a result of intensive research, the present inventors have found that a compound represented by general formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof inhibits DNA gyrase GyrB subunit and/or topoisomerase IV ParE subunit possesses excellent solubility and a safety profile for use in humans for the treatment of bacterial infectious diseases.Type: GrantFiled: September 28, 2016Date of Patent: September 3, 2019Assignee: Daiichi Sankyo Company, LimitedInventors: Manoj Kumar Khera, Tarun Mathur, Jitendra A. Sattigeri, Nobuhisa Masuda, Tsuyoshi Soneda, Yoshiko Kagoshima, Toshiyuki Konosu, Tetsuya Suzuki, Makoto Yamaoka, Ryo Itooka
-
Publication number: 20180327399Abstract: Problem to be Solved There is a need for a new antibiotic having a novel mechanism of action which exhibit strong antibacterial activity not only against sensitive bacteria but also against resistant bacteria thereof, and at the same time possesses excellent solubility an a safety profile amenable to human use. Solution to the Problem As a result of intensive research, the present inventors have found that a compound represented by general formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof inhibits DNA gyrase GyrB subunit and/or topoisomerase IV ParE subunit possesses excellent solubility and a safety profile for use in humans for the treatment of bacterial infectious diseases.Type: ApplicationFiled: September 28, 2016Publication date: November 15, 2018Applicant: Daiichi Sankyo Company, LimitedInventors: Manoj Kumar Khera, Tarun Mathur, Jitendra A. Sattigeri, Nobuhisa Masuda, Tsuyoshi Soneda, Yoshiko Kagoshima, Toshiyuki Konosu, Tetsuya Suzuki, Makoto Yamaoka, Ryo Itooka
-
Patent number: 10040791Abstract: It has been found that a compound of the general formula (I) having an isoxazole skeleton has excellent inhibitory activity against mutant IDH1 protein and inhibits the production of 2-HG by this protein, while the compound is also capable of effectively inhibiting the growth of various tumors expressing the protein. In the formula, R1, R2, R3, Y, and Z are as defined in claim 1.Type: GrantFiled: October 1, 2015Date of Patent: August 7, 2018Assignees: Daiichi Sankyo Company, Limited, National Cancer CenterInventors: Shoichi Saito, Masao Itoh, Tetsunori Fujisawa, Hironao Saito, Yohei Kiyotsuka, Hideaki Watanabe, Hironori Matsunaga, Yoshiko Kagoshima, Tetsuya Suzuki, Yoko Ogawara, Kazuo Kitabayashi
-
Publication number: 20170313696Abstract: It has been found that a compound of the general formula (I) having an isoxazole skeleton has excellent inhibitory activity against mutant IDH1 protein and inhibits the production of 2-HG by this protein, while the compound is also capable of effectively inhibiting the growth of various tumors expressing the protein. In the formula, R1, R2, R3, Y, and Z are as defined in claim 1.Type: ApplicationFiled: October 1, 2015Publication date: November 2, 2017Applicants: Daiichi Sankyo Company, Limited, National Cancer CenterInventors: Shoichi Saito, Masao Itoh, Tetsunori Fujisawa, Hironao Saito, Yohei Kiyotsuka, Hideaki Watanabe, Hironori Matsunaga, Yoshiko Kagoshima, Tetsuya Suzuki, Yoko Ogawara, Kazuo Kitabayashi
-
Patent number: 9751887Abstract: The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.Type: GrantFiled: October 29, 2015Date of Patent: September 5, 2017Assignee: Daiichi Sankyo Company, LimitedInventors: Yasuyuki Takeda, Kenji Yoshikawa, Yoshiko Kagoshima, Yuko Yamamoto, Ryoichi Tanaka, Yuichi Tominaga, Masaki Kiga, Yoshito Hamada
-
Publication number: 20160046639Abstract: The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.Type: ApplicationFiled: October 29, 2015Publication date: February 18, 2016Applicant: Daiichi Sankyo Company, LimitedInventors: Yasuyuki Takeda, Kenji Yoshikawa, Yoshiko Kagoshima, Yuko Yamamoto, Ryoichi Tanaka, Yuichi Tominaga, Masaki Kiga, Yoshito Hamada
-
Patent number: 9187489Abstract: The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.Type: GrantFiled: June 3, 2013Date of Patent: November 17, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Yasuyuki Takeda, Kenji Yoshikawa, Yoshiko Kagoshima, Yuko Yamamoto, Ryoichi Tanaka, Yuichi Tominaga, Masaki Kiga, Yoshito Hamada
-
Publication number: 20150051190Abstract: The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.Type: ApplicationFiled: June 3, 2013Publication date: February 19, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Yasuyuki Takeda, Kenji Yoshikawa, Yoshiko Kagoshima, Yuko Yamamoto, Ryoichi Tanaka, Yuichi Tominaga, Masaki Kiga, Yoshito Hamada
-
Patent number: 8927588Abstract: To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient.Type: GrantFiled: September 13, 2013Date of Patent: January 6, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Soneda, Hiroshi Takeshita, Yoshiko Kagoshima, Yuko Yamamoto, Takafumi Hosokawa, Toshiyuki Konosu, Nobuhisa Masuda, Takuya Uchida, Issei Achiwa, Junichi Kuroyanagi, Tetsunori Fujisawa, Aki Yokomizo, Tetsuji Noguchi
-
Publication number: 20140073622Abstract: To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient.Type: ApplicationFiled: September 13, 2013Publication date: March 13, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Soneda, Hiroshi Takeshita, Yoshiko Kagoshima, Yuko Yamamoto, Takafumi Hosokawa, Toshiyuki Konosu, Nobuhisa Masuda, Takuya Uchida, Issei Achiwa, Junichi Kuroyanagi, Tetsunori Fujisawa, Aki Yokomizo, Tetsuji Noguchi
-
Patent number: 8536197Abstract: An antibiotic compound having a novel mechanism of action, weak cytotoxicity, high solubility in water, effective in inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and having antibacterial activity.Type: GrantFiled: December 26, 2008Date of Patent: September 17, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Soneda, Hiroshi Takeshita, Yoshiko Kagoshima, Yuko Yamamoto, Takafumi Hosokawa, Toshiyuki Konosu, Nobuhisa Masuda, Takuya Uchida, Issei Achiwa, Junichi Kuroyanagi, Tetsunori Fujisawa, Aki Yokomizo, Tetsuji Noguchi
-
Publication number: 20100311966Abstract: An antibiotic compound having a novel mechanism of action, weak cytotoxicity, high solubility in water, effective in inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and having antibacterial activity.Type: ApplicationFiled: December 26, 2008Publication date: December 9, 2010Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsuyoshi Soneda, Hiroshi Takeshita, Yoshiko Kagoshima, Yuko Yamamoto, Takafumi Hosokawa, Toshiyuki Konosu, Nobuhisa Masuda, Takuya Uchida, Issei Achiwa, Junichi Kuroyanagi, Tetsunori Fujisawa, Aki Yokomizo, Tetsuji Noguchi
-
Patent number: 7230023Abstract: A triazole compound of the formula (I) or a pharmacologically salt thereof: wherein X represents a group of formula X—OH which has antifungal activity, L represents an -(adjacently substituted C6-C10 aryl)-CH2 group and R represents a —P(?O)(OH)2 group.Type: GrantFiled: August 20, 2003Date of Patent: June 12, 2007Assignee: Sankyo Company, LimitedInventors: Makoto Mori, Yoshiko Kagoshima, Takuya Uchida, Toshiyuki Konosu, Takahiro Shibayama
-
Publication number: 20040198790Abstract: A triazole compound of the formula (I) or a pharmacologically salt thereof: 1Type: ApplicationFiled: August 20, 2003Publication date: October 7, 2004Applicant: SANKYO COMPANY, LIMITEDInventors: Makoto Mori, Yoshiko Kagoshima, Takuya Uchida, Toshiyuki Konosu, Takahiro Shibayama